收藏切换
Budget impact analysis of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma
收藏切换
Yun YANG1, Na ZHAO2, Yan XU3, Yang ZHAO3, *
World Clinical Drug | 2025, 46(5) : 465 - 470
Less
收藏切换
World Clinical Drug | 2025, 46(5): 465-470
• Article •
Budget impact analysis of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma
Full
Yun YANG1, Na ZHAO2, Yan XU3, Yang ZHAO3, *
Affiliations
  • 1.Henan Medical Price and Bidding Procurement Service Center, Zhengzhou 450000; Henan Province, China
  • 2.Henan Medical College, Zhengzhou 450000; Henan Province, China
  • 3.Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450000; Henan Province, China
Published: 2025-05-10 doi: 10.13683/j.wph.2025.05.007
Outline
收藏切换
Objective

To evaluate the budget impact of the combination therapy of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma after its inclusion in the China's National Reimbuirsement Drug List (NRDL).

Methods

This study constructed a 5-year (2024—2028) budget impact analysis model from the perspective of the Chinese government health insurance authority to simulate the budget changes after the combination therapy of nivolumab and ipilimumab was included in the NRDL. The model analyzed factors such as the target population, drug market share, and treatment costs, comparing healthcare expenditures in scenarios with and without insurance coverage.One-way sensitivity analysis was performed to assess model robustness.

Results

After inclusion in the NRDL, the incremental expenditure from 2024 to 2028 mainly stems from health insurance payment portion of drug costs, with a cumulative increase of 66.645 million yuan. However, the overall financial impact on the insurance fund remains minimal.Sensitivity analysis showed that drug prices, reimbursement rates, and insurance coverage rates were the key factors affecting budget changes.

Conclusion

Although the combination therapy of nivolumab and ipilimumab included in the NRDL will increase expenditure, the impact on the overall fund burden is limited.

malignant pleural mesothelioma  /  budget impact analysis  /  nivolumab  /  ipilimumab  /  insurance reimbursement  /  National Reimbuirsement Drug List
杨运, 赵娜, 徐燕, 赵杨. 纳武利尤单抗联合伊匹木单抗用于治疗不可手术切除恶性胸膜间皮瘤的预算影响分析. 世界临床药物, 2025 , 46 (5) : 465 -470 . DOI: 10.13683/j.wph.2025.05.007
Yun YANG, Na ZHAO, Yan XU, Yang ZHAO. Budget impact analysis of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma[J]. World Clinical Drug, 2025 , 46 (5) : 465 -470 . DOI: 10.13683/j.wph.2025.05.007
Year 2025 volume 46 Issue 5
54
11
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.05.007
  • Receive Date:2024-11-23
  • Online Date:2026-11-09
  • Published:2025-05-10
Article Data
Affiliations
History
  • Received:2024-11-23
Affiliations
    1.Henan Medical Price and Bidding Procurement Service Center, Zhengzhou 450000; Henan Province, China
    2.Henan Medical College, Zhengzhou 450000; Henan Province, China
    3.Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450000; Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.05.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT